Striking inflammation from both sides: Manganese(II) pentaazamacrocyclic SOD mimics act also as nitric oxide dismutases: A single-cell study

Angewandte Chemie - International Edition

Volumn 49, Issue 25, 2010, Pages 4228-4232

  Filipović, Miloš R ^a   Koh, Alario C W ^b   Arbault, Stéphane ^b   Niketić, Vesna ^d   Debus, Andrea ^c   Schleicher, Ulrike ^c   Bogdan, Christian ^c   Guille, Manon ^b   Lemaître, Frédéric ^b   Amatore, Christian ^b   Ivanović Burmazović, Ivana ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Inflammation; Macrocyclic ligands; Manganese; Nitric oxide; Sod mimics

Indexed keywords

AMPEROMETRY; CYTOTOXIC EFFECTS; INFLAMMATION; MACROCYCLIC LIGANDS; PENTAAZAMACROCYCLIC; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN; SINGLE CELLS;

LIGANDS; MANGANESE; NITRIC OXIDE; OXYGEN; PATHOLOGY;

MANGANESE OXIDE;

BIOMIMETIC MATERIAL; HETEROCYCLIC COMPOUND; INDUCIBLE NITRIC OXIDE SYNTHASE; MACROCYCLIC COMPOUND; MANGANESE; MESSENGER RNA; NITRIC OXIDE; NOS2 PROTEIN, MOUSE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL; ARTICLE; CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; INFLAMMATION; MACROPHAGE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; AZA COMPOUNDS; BIOMIMETIC MATERIALS; CELL LINE; CELL SURVIVAL; INFLAMMATION; MACROCYCLIC COMPOUNDS; MACROPHAGES; MANGANESE; MICE; MOLECULAR STRUCTURE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 77953485055     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.200905936     Document Type: Article

References (36)

1. T. J. Guzik, R. Korbut, T. Adamek-Guzik, J. Physiol. Pharmacol. 2003, 54, 469-487.
2. C. Szabó, H. Ischiropoulos, R. Radi, Nat. Rev. Drug Discovery 2007, 6, 662-680.
3. a) P. Vallance, J. Leiper, Nat. Rev. Drug Discovery 2002, 1, 939-950;
4. b) D. Salvemini, D. Riley, S. Cuzzocrea, Nat. Rev. Drug Discovery 2002, 1, 367-374;
5. c) B. Hauser, H. Bracht, M. Matejovic, P. Radermacher, B. Venkatesh, Crit. Care Trauma 2005, 101, 488-498;
6. d) C. Muscoli, S. Cuzzocrea, D. P. Riley, J. L. Zweier, C. Thiemermann, Z. Q. Wang, D. Salvemini, Br. J. Pharmacol. 2003, 140, 445-460.
7. a) D. Salvemini, Z. Q. Wang, J. L. Zweier, A. Samouilov, H. Macarthur, T. P. Misko, M. G. Currie, S. Cuzzocrea, J. A. Sikorski, D. P. Riley, Science 1999, 286, 304-306;
8. b) D. Salvemini, T. M. Doyle, S. Cuzzocrea, Biochem. Soc. Trans. 2006, 34, 965-970;
9. c) E. Masini, S. Cuzzocrea, E. Mazzon, C. Marzocca, P. F. Mannaioni, D. Salvemini, Br. J. Pharmacol. 2002, 136, 905-917;
10. d) C. Di Filippo, S. Cuzzocrea, R. Marfella, V. Fabbroni, G. Scollo, L. Berrino, D. Giugliano, F. Rossi, M. D'Amico, Eur. J. Pharmacol. 2004, 497, 65-74;
11. e) D. Salvemini, E. Mazzon, L. Dugo, D. P. Riley, I. Serraino, A. P. Caputi, S. Cuzzocrea, Br. J. Pharmacol. 2001, 132, 19-29.
12. a) M. R. Filipović, D. Stanić, S. Raičević, M. Spasić, V. Niketić, Free Radical Res. 2007, 41, 62-72;
13. b) M. R. Filipović, K. Duerr, M. Mojović, V. Simeunović, R. Zimmermann, V. Niketić, I. Ivanović- Burmazović, Angew. Chem. 2008, 120, 8863-8867;
14. Angew. Chem. Int. Ed. 2008, 47, 8735-8739.
15. II complexes of this class are all present as diaqua species (for solution property and stability of manganese(II) pentaazamacrocyclic complexes see: A. Dees, A. Zahl, R. Puchta, N. J. R. van Eikema Hommes, F. W. Heinemann, I. Ivanovic-Burmazovic, Inorg. Chem. 2007, 46, 2459-2470).
16. a) C. Bogdan, M. Röllinghoff, A. Diefenbach, Cuir. Opin. Immunol. 2000, 12, 64-76;
17. b) C. Bogdan, Nat. Immunol. 2001, 2, 907-916.
18. C. Amatore, S. Arbault, M. Guille, F. Lemaitre, Chem. Rev. 2008, 108, 2585-2621.
19. The complex should be used at sufficiently low concentrations to present low toxicity to RAW 264.7 macrophages and exclude the detection of ROS/RNS released by apoptotic cells. Conversely, a sufficiently high concentration was needed for the effects from the Mn SOD mimic to be more apparent. These boundaries defined the experimental concentration range used in this study.
20. Experimental details, as well as supporting text and references, are given in the Supporting Information.
21. a) ID. Burton, Methods Mol. Med. 2005, 110, 69-78;
22. b) The addition of cytotoxic agents will lead to metabolic dysfunction, and consequently a lower rate of MTT reduction.
23. Cells to which the mimic was added remained largely similar to the control cells. Although the activation by IFN-γ and LPS of cells leads to the expression of iNOS and an increased endocytic activity, co-treatment with the mimic did not lead to any significant morphological differences in comparison with cells that had been activated in the presence of IFN-γ/LPS only.
24. a) C. Amatore, S. Arbault, C. Bouton, J.C. Drapier, H. Ghandour, A. Koh, ChemBioChem 2008, 9, 1472-1480;
25. b) C. Amatore, S. Arbault, C. Bouton, K. Coffi, J. C. Drapier, H. Ghandour, Y. H. Tong, ChemBioChem 2006, 7, 653-661;
26. c) C. Amatore, S. Arbault, D. Bruce, P. de Oliveira, M. Erard, M. Vuillaume, Faraday Discuss. 2000, 116, 319-333.
27. C. Nathan, Q. W. Xie, J. Biol. Chem. 1994, 269, 13725-13728.
28. a) M. N. Hughes, Biochim. Biophys. Acta Bioenerg. 1999, 1411, 263-272;
29. b) J. M. Fukuto, A. S. Dutton, K. N. Houk, ChemBioChem 2005, 6, 612-619;
30. c) S. Lymar, V. Shafirovich, G. A. Poskrebyshev, Inorg. Chem. 2005, 44, 5212-5221;
31. d) S. Lymar, R. F. Khairutdinov, J. K. Hurst, Inorg. Chem. 2003, 42, 5259-5266;
32. e) A. Denicola, B. Freeman, M. Trujillo, R. Radi, Arch. Biochem. Biophys. 1996, 333, 49-58.
33. M. N. Alvarez, L. Piacenza, F. Irigoin, G. Peluffo, R. Radi, Arch. Biochem. Biophys. 2004, 432, 222-232.
34. C. Amatore, S. Arbault, D. Bruce, P. de Oliveira, M. Erard, M. Vuillaume, Chem. Eur. J. 2001, 7, 4171-4179.
35. - concentration.
36. - oxidation was not considered here.